Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
With the regulated medical use of psilocybin and MDMA, Australia has taken a path no other country has followed so far. A review published in the British Journal of Pharmacology examines the background of the decision and its possible consequences for the further development of psychedelic medicines.
The Australian Therapeutic Goods Administration (TGA) rescheduled psilocybin and MDMA in 2023, with the new rules taking effect on July 1, 2023. Since then, psilocybin can be used under specific conditions to treat treatment-resistant depression, while MDMA is restricted to the treatment of post-traumatic stress disorder (PTSD). Prescribing is reserved exclusively for psychiatrists approved as so-called Authorised Prescribers under the TGA program.
The authors David Nutt, Peter Hunt, Anne Katrin Schlag, and Paul Fitzgerald place the decision in the context of the strong expansion of clinical research on psychedelics and MDMA and the persistently high unmet need in the treatment of mental illness. A central role in the political campaign for the TGA decision was played by the Australian organization Mind Medicine Australia, supported among others by scientists, the organization Drug Science, and clinical, academic, and patient groups.
The paper reads Australia’s approach as more than a national regulatory decision. The authors also discuss what the Australian path could mean for possible approvals in other countries and for the development of further psychedelic medicines. The publication thus doubles as a stocktaking of Australia’s so far unusual model for the clinical use of psychedelics.
